Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 291.42% | -- | -14.17% | -82.53% | -82.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 291.42% | -- | -14.17% | -82.53% | -82.53% |
| Cost of Revenue | -- | -- | 402.74% | -100.00% | -100.00% |
| Gross Profit | 206.74% | -- | -26.81% | -82.00% | -82.00% |
| SG&A Expenses | 15.26% | -11.72% | -12.78% | -18.00% | -30.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.52% | 16.68% | 17.12% | 6.13% | 4.26% |
| Operating Income | -8.21% | -0.01% | -24.82% | -28.37% | -25.47% |
| Income Before Tax | 10.74% | 17.50% | 1.59% | -72.55% | -65.81% |
| Income Tax Expenses | 158.64% | 164.05% | 164.05% | -- | -- |
| Earnings from Continuing Operations | 7.85% | 14.17% | -2.96% | -69.27% | -62.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.85% | 14.17% | -2.96% | -69.27% | -62.64% |
| EBIT | -8.21% | -0.01% | -24.82% | -28.37% | -25.47% |
| EBITDA | -6.19% | 2.46% | -23.56% | -31.38% | -27.51% |
| EPS Basic | 10.88% | 16.67% | -0.20% | -50.13% | -25.05% |
| Normalized Basic EPS | -9.74% | -1.95% | -29.55% | -20.43% | -0.29% |
| EPS Diluted | 10.88% | 16.67% | -0.20% | -50.13% | -25.05% |
| Normalized Diluted EPS | -9.74% | -1.95% | -29.55% | -20.43% | -0.29% |
| Average Basic Shares Outstanding | 3.32% | 3.07% | 6.34% | 13.73% | 23.95% |
| Average Diluted Shares Outstanding | 3.32% | 3.07% | 6.34% | 13.73% | 23.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |